secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oyster Point Pharma, Inc. (—)
CIK:        0001720725
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001193125-23-000324
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.03, 5.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris acquires Oyster Point Pharma for $11/sh cash plus CVR; deal closed Jan 3, 2023
--------------------------------------------------------------------------------

- Viatris completes acquisition of Oyster Point for $11.00/sh cash plus CVR up to $2.00/sh.
- Total cash consideration ~$298.8M (excluding CVR); OrbiMed debt of ~$298.8M repaid in full.
- Approx. 85.3% of shares validly tendered prior to offer expiration; remaining shares converted in merger.
- CVR milestones: $1/sh if 2022 net rev ≥$21.6M and Rxs ≥131,822; $2/sh if ≥$24.0M and 146,469 Rxs.
- All pre-merger directors resigned; Oyster Point to be delisted from Nasdaq (symbol OYST).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720725/000119312523000324/0001193125-23-000324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720725/000119312523000324/d438605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-000324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer